A progress report on the University Group Diabetes Program.
The increase in cardiovascularortality associated with the use of oral hypoglycemic agents is emphasized. It is important that clinical pharmacologists take a more positive stand against the use of medications that have added risks that are not offset by actual benefits to the patient.
D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000401:mortality; D003925:Diabetic Angiopathies / Q000401:mortality / Q000517:prevention & control*; D004345:Drug Industry; D005102:Health Expenditures; D006801:Humans; D007049:Iatrogenic Disease; D007328:Insulin / Q000627:therapeutic use; D008396:Maryland; D009203:Myocardial Infarction / Q000401:mortality / Q000517:prevention & control; D010629:Phenformin / Q000627:therapeutic use; D014044:Tolbutamide / Q000627:therapeutic use
D007328:Insulin; D014044:Tolbutamide; D010629:Phenformin